Prescribing patterns of tricyclic and selective serotonin reuptake inhibitor antidepressants among a sample of adolescents and young adults

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 5, 2003, Pages 379-382

  Kairuz, Therèse ^a   Truter, Ilse ^b   Hugo, Johan ^b   Foxcroft, Cheryl ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

Author keywords

Adolescents; Amitryptiline; Antidepressants; Fluoxetine; Selective serotonin reuptake inhibitor antidepressants; Tricyclic antidepressants; Young adults

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; FLUOXETINE; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; TABLET;

ADOLESCENT; ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DRUG UTILIZATION; FEES, PHARMACEUTICAL; FEMALE; FLUOXETINE; HEALTH SERVICES RESEARCH; HUMANS; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0041869429     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.854     Document Type: Article

References (16)

1. Patton GC, Bowes G. Recognising the warning signs of youth suicide. Curr Ther 1998; 55-58.
2. Gilbert P. Overcoming Depression: A Self-Help Guide to Using Cognitive Behavioural Techniques. Robinson: London, 1997; 17.
3. Son SE, Kirchner JT. Depression in children and adolescents. Am Fam Physician 2000; at http://www.aafp.org/afp/20001115/2297.html [16 May 2002].
4. Weller EB, Weller RA. Treatment options in the management of adolescent depression. J Affect Disord 2000; 61: 23-28.
5. Donoghue JM, Tylee A. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996; 168: 164-168.
6. Skaer TL, Robison LM, Sclar DA, Galin RS. Treatment of depressive illness among children and adolescents in the United States. Curr Ther Res 2000; 61(10): 692-705.
7. Rudorfer MV, Potter WZ. Role of antidepressants metabolites in the treatment of depression. In Drug Treatment Issues in Depression, Palmer KJ (ed.). Adis International: Auckland, 2000; 97-140.
8. ATC Index with DDDs 2001. WHO Collaborating Centre for Drug Statitiscs Methodology. Kalbakken: Norway, 2001.
9. Egberts ACG, Veenstra M, De Jong-Van Den Berg LTW. Anti-depressant drug choice for first users in two regions in the Netherlands. Pharm World Sci 1999; 21: 132-136.
10. Van Marwijk HWJ, Bijl D, Adér HJ, De Haan M. Anti-depressant prescription for depression in general practice in the Netherlands. Pharm World Sci 2001; 23: 46-49.
11. Lawrenson RA, Tyrer F, Newson RB, Farmer RDT. TCA/SSRI prescribing up in UK, but suboptimal dosing common. PharmacoEconomics Outcomes News 2000; 281: 6.
12. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG. Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland. Br Med J 1996; 313: 860-861.
13. McGettigan P, Kelly A, Carvahlo M, Feely J. Antidepressants in primary care: Analysis of treatment discontinuations. Pharmacoepidemiol Drug Safe 2000; 9(6): 521-528.
14. Truter I, Kotze TJ Van Wyk. An investigation into the prescribed daily dose of fluoxetine. S Afr Med J 1997; 87(12): 1738-1743.
15. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a medicaid population. J Clin Psychiatry 1990; 51(6): 60-69.
16. Rawson NS, Blackburn JL, Baker MJ. Prescription episodes to study drug utilization with the Saskatchewan drug plan data-file. J Soc Adm Pharm 1998; 15(4): 241-251.